Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
After Aktis's $318m flotation Eikon is a bigger proposition.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
ELVN-001 is made to look more like Terns’ TERN-701.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
But Tevimbra’s role looks shaky as adverse events loom.
